MedTrace Logo

Genetic Risk-Based Atrial Fibrillation Screening (GeneAF Study)

NCT04932798 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 726

Last updated 2022-09-01

No results posted yet for this study

Summary

AF is the most common sustained arrhythmia in adults and its prevalence increases with advancing age.

In this study, we aim to determine whether the published genome-wide polygenic scores for atrial fibrillation (GPSAF) can facilitate AF screening by accurately discriminating between patients with low and high risk for AF.

All included patients are participating in the MHI biobank, an ongoing funded institutional DNA bank and clinical registry approved by the research ethics board where included patients consent for future genetic research.

The study will compare AF detection rate using a 3 months near continuous monitoring in individuals with a high GPSAF with matched individuals from the bottom GPSAF.

Conditions

Interventions

DIAGNOSTIC_TEST

Resting ECG (if first visit is done on site only)

The standard 12-lead electrocardiogram is a representation of the heart's electrical activity recorded from electrodes on the body surface. This test requires around 15 minutes of the participant's time.

DIAGNOSTIC_TEST

24-hour ambulatory electrocardiographic monitoring (Holter) (if first visit done on site only)

The Holter monitor is a type of portable electrocardiogram (ECG) worn continuously for 24 hours.

DIAGNOSTIC_TEST

3-month AF detection monitoring using the Apple Watch

Patients with irregular heart rates will be notified by the Apple Watch and instructed to confirm the rhythm by using the integrated ECG recording system. This simply requires touching the watch with a finger from the opposite hand and provides a 30 seconds one-lead ECG recording of diagnostic quality. These tracing will be transferred to the study team for analysis using a dedicated email.

Sponsors & Collaborators

  • Montreal Heart Institute

    lead OTHER

Principal Investigators

  • Julia Cadrin-Tourigny, MD · Montreal Heart Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2026-01-10
Completion
2026-01-10

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04932798 on ClinicalTrials.gov